John Frederick Ek - 20 Mar 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: CFO
Signature: /s/ John Frederick Ek, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 20 Mar 2023
Transactions value $: $0
Form type: 4
Filing time: 21 Mar 2023, 17:51:38 UTC
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+160K		$0.00	160K	20 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Award	$0	+160K		$0.00	160K	20 Mar 2023	Common Stock	160K	$7.60	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in four (4) equal annual installments beginning on April 1, 2024, and annually thereafter until fully vested.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3	The options shall vest as follows: twenty-five percent (25%) shall vest on March 20, 2024 with the remainder vesting in 36 equal monthly installments beginning on April 20, 2024.